OncoCyte Corp (NAS:OCX)
$ 2.44 0.005 (0.21%) Market Cap: 41.08 Mil Enterprise Value: 41.71 Mil PE Ratio: 0 PB Ratio: 3.36 GF Score: 33/100

OncoCyte Corp at UBS Genomics 2.0 and MedTech Innovations Summit Transcript

Aug 11, 2022 / 09:00PM GMT
Release Date Price: $19.56 (+2.83%)
Elizabeth Cristina Mari Garcia
UBS Investment Bank, Research Division - US Life Science Analyst

All right. Hello. Welcome, everybody. You've got me back, Liza Garcia, UBS Life Science Tools & Diagnostics Analyst. And I am very, very fortunate as I am joined here by the CEO of OncoCyte. And he will be diving into some fireside chat questions. So thank you very much for joining me.

Ronald A. Andrews
OncoCyte Corporation - President, CEO & Director

Thanks for having me.

Questions & Answers

Elizabeth Cristina Mari Garcia;Ronald A. Andrews
UBS Investment Bank, Research Division - US Life Science Analyst;OncoCyte Corporation -

Great. Awesome. So I was thinking maybe we'll start off with the portfolio and kind of walk through it and kind of get a lay of the land for people who may not be as familiar with the OncoCyte story. So let's start off with DetermaRx, the lung cancer stratification test. Could you maybe walk us through the use case here? Let's start there.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot